KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
News RSS